Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings

J Am Coll Cardiol. 2006 May 16;47(10):2108-11. doi: 10.1016/j.jacc.2005.11.092. Epub 2006 Apr 4.

Abstract

Objectives: The goal of this study was to use angioscopy to investigate the amount of neointimal coverage after sirolimus-eluting stent (SES) implantation.

Background: Sirolimus-eluting stents reduce intimal hyperplasia.

Methods: We used angioscopy to evaluate 37 consecutive stented coronary artery lesions (15 SES and 22 bare-metal stents [BMS]) in 25 patients (18 men, 7 women) at 3 to 6 months after stent implantation. Angioscopic evaluation focused on: 1) neointimal coverage of stent struts, and 2) the existence of thrombi. The degree of neointimal coverage was classified as grade 0 when there was no neointimal coverage (similar to immediately after the implantation); grade 1 when stent struts bulged into the lumen, but were covered and still translucently visible; grade 2 when stent struts were visible but not clearly seen (not translucent); and grade 3 when stent struts were not visible because they were embedded in the neointima.

Results: Thrombi were identified in eight stented segments, tended to be more common with SES (p = 0.14), but were not seen on angiography. Three of the 15 SES (20%) had grade 0 neointimal coverage, and only 2 SES (13.3%) had complete coverage (grades 2/3). In contrast, all 22 BMS showed complete intimal coverage (grades 2/3). Thrombi were more common in stents with incomplete neointimal coverage (p = 0.09).

Conclusions: The SES had incomplete neointimal coverage three to six months after implantation, and this was associated with subclinical thrombus formation.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Angioscopy*
  • Blood Vessel Prosthesis Implantation / adverse effects
  • Coronary Angiography
  • Coronary Restenosis / diagnosis
  • Coronary Restenosis / etiology
  • Coronary Restenosis / prevention & control
  • Coronary Stenosis / therapy
  • Coronary Thrombosis / diagnosis*
  • Coronary Thrombosis / etiology
  • Coronary Thrombosis / prevention & control
  • Delayed-Action Preparations
  • Female
  • Humans
  • Hyperplasia
  • Immunosuppressive Agents / administration & dosage*
  • Immunosuppressive Agents / adverse effects
  • Male
  • Middle Aged
  • Sirolimus / administration & dosage*
  • Sirolimus / adverse effects
  • Stents / adverse effects*
  • Tunica Intima / drug effects*
  • Tunica Intima / pathology
  • Wound Healing / drug effects

Substances

  • Delayed-Action Preparations
  • Immunosuppressive Agents
  • Sirolimus